Arrien Pharmaceuticals
Arrien Pharmaceuticals, a US-based company, specializes in pharmaceuticals from its Salt Lake City location.
Founded
2011Arrien Pharmaceuticals, a US-based company, specializes in pharmaceuticals from its Salt Lake City location.
Arrien Pharmaceuticals, founded in Salt Lake City, specializes in developing targeted cancer therapeutics. The company's core mission is to innovate in the field of fragment-based drug discovery to create effective clinical candidates. Their product pipeline includes several promising compounds such as GRN300 (ARN-3261), ARN-0953, SLX-0528 (XT-0528/BOS-172767/ARN-6039), and OR-101 (ARN-4079). Arrien Pharmaceuticals focuses on addressing unmet medical needs in oncology through advanced technology-driven solutions.
The leadership team at Arrien Pharmaceuticals comprises experienced professionals in the pharmaceutical industry, contributing to its strategic direction and innovation. The company has made significant strides in its research and development efforts, with multiple compounds advancing through the pipeline. Arrien's impact on the pharmaceutical market is marked by its commitment to bringing new, targeted cancer therapies to patients, potentially transforming treatment paradigms and improving patient outcomes.
Companies similar to Arrien Pharmaceuticals include Aria Pharmaceuticals, Arisaph Pharmaceuticals, Argentis Pharmaceuticals and Marillion Pharmaceuticals.
Arrien Pharmaceuticals was founded in 2011.
Arrien Pharmaceuticals' headquarters is located in Ansonia, CT, US.
Arrien Pharmaceuticals' most recent funding round was for $2M (USD) in September 2011.
As of Sep 13, 2011, Arrien Pharmaceuticals has disclosed funding of $2M (USD). Undisclosed round amounts are excluded.
Arrien Pharmaceuticals has 7 employees as of Feb 4, 2024.
Marillion Pharmaceuticals
